Pipeline

Initial Targeted Indications

Indication
Targeted Subgroup
Formulation
Unique selling point (USP)
© Dale Biotech LLC 2021. All Rights Reserved.
Non-alcoholic Steatohepatitis (NASH)
NASH patients especially those with diabetes
Oral
Combination therapy addresses the multiple drivers of NASH progression to cirrhosis and liver failure driven by endothelial disfunction and inflammation. These factors also drive cardiovascular risk and peripheral artery disease, and increased risk of severe COVID-19. Niclosamide has potent efficacy against virus variants of COVID-19.

Additional Development Opportunities

Indication
Targeted Subgroup
Formulation
Unique selling point (USP)
© Dale Biotech LLC 2021. All rights reserved.
Body Sculpting
Double chin
Injectable
Significantly less inflammation than currently marketed injectable; Single treatment efficacy expected to be sufficient in majority of clients
Central abdominal bulge
Injectable
No available injectable
Dupuytren’s Disease
Progressive contractures post hand surgery or Xiaflex injection(s)
Injectable sustained release
Large unmet medical need for effective disease modifying treatment
Progressive contractures post hand surgery or Xiaflex injection(s)
Topical
Large market for effective treatment that can be patient-administered
Cellulite
Cellulite of lateral and posterior buttocks
Subcutaneous-injectable
Direct action of adipocytes